Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Ophthalmol ; 22(1): 264, 2022 Jun 13.
Article in English | MEDLINE | ID: mdl-35698056

ABSTRACT

BACKGROUND: To estimate macular pigment values in macular telangiectasia (MacTel) Type 2 in comparison with healthy subjects in the South Indian population across different spatial profiles and to quantify the regional differences of macular pigment optical density (MPOD) in MacTel Type 2. METHODS: In this prospective cross-sectional study, healthy controls and patients diagnosed with various stages of MacTel Type 2 underwent MPOD measurement using dual-wavelength autofluorescence technique with Spectralis HRA + OCT. RESULTS: Sixty eyes of 31 healthy subjects and 41 eyes of 22 MacTel type 2 patients were included. We found an overall decrease in MPOD values in MacTel type 2 patients (-0.109, -0.11, -0.001) in comparison with healthy subjects (0.38, 0.23, 0.06) at 1°, 2° & 6° foveal eccentricities (P < 0.001). In various stages of MacTel type 2, the mean MPOD was found to be higher in the peripheral region compared to the central region. We found a significantly lower mean MPOD in the central region in association with specific optical coherence tomography (OCT) parameters like inner retinal cavities (P = 0.035) and ellipsoid zone disruption (P = 0.034). CONCLUSIONS: In MacTel type 2, MPOD distribution varies in different spatial profiles with higher MPOD levels in the peripheral region compared to the central region. The macular pigment levels are associated with inner retinal cavities and ellipsoid zone disruption seen on OCT.


Subject(s)
Macular Pigment , Retinal Telangiectasis , Cross-Sectional Studies , Humans , Prospective Studies , Retinal Telangiectasis/diagnosis , Tomography, Optical Coherence/methods , Visual Acuity
2.
Int Ophthalmol ; 42(1): 157-166, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34424436

ABSTRACT

PURPOSE: To describe the clinical features, management, and outcomes of choroidal neovascularization (CNV) in children less than 18 years of age. METHODS: This was a retrospective, case control study of 111 eyes of 96 patients. CNV was clinically diagnosed in all patients. Eyes were classified as those that were observed (Controls; Group 1) or those that had treatment (Cases; Group 2). CNV was categorized as regressed, persistent, or recurrent in order to evaluate the anatomical outcomes. RESULTS: Of 96 patients, 68(71%) were male. Mean presenting age was 11.4 ± 3.4 years (median = 11 years, range = 1-17 years). CNV was bilateral in 15(16%) patients. Of 111 eyes, 38 eyes had treatment (Cases) and 73 eyes did not (Natural history group or Controls). Subfoveal CNV was seen in majority of cases (59%). Most common etiology was post-inflammatory (38%), followed by trauma (16%). Eyes were classified as those that were observed (controls; Group 1) or those that had treatment (cases; Group 2). In group 1, spontaneous regression of CNV was seen in 26(36%) eyes and there was no recurrence in this group. In group 2 following treatment, 25(66%) of 38 eyes achieved complete regression at mean 4.9 months and was persistent in 5 eyes. CNV recurrence was seen in 10 eyes with the mean time to first recurrence being 9 months. At presentation, mean best-corrected visual acuity (BCVA) of eyes with subfoveal CNV was logMAR 0.99 that improved to logMAR 0.63 with treatment. Mean follow-up was 17 months. CONCLUSION: CNV results in significant visual decline in children; most commonly of post-inflammatory etiology. Treatment achieves high regression rates, albeit with limited visual improvement.


Subject(s)
Choroidal Neovascularization , Adolescent , Case-Control Studies , Child , Child, Preschool , Choroidal Neovascularization/diagnosis , Choroidal Neovascularization/etiology , Fluorescein Angiography , Follow-Up Studies , Fovea Centralis , Humans , Infant , Male , Retrospective Studies , Treatment Outcome , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...